PH12016502258A1 - Improved polyethyleneimine polyethyleneglycol vectors - Google Patents

Improved polyethyleneimine polyethyleneglycol vectors

Info

Publication number
PH12016502258A1
PH12016502258A1 PH12016502258A PH12016502258A PH12016502258A1 PH 12016502258 A1 PH12016502258 A1 PH 12016502258A1 PH 12016502258 A PH12016502258 A PH 12016502258A PH 12016502258 A PH12016502258 A PH 12016502258A PH 12016502258 A1 PH12016502258 A1 PH 12016502258A1
Authority
PH
Philippines
Prior art keywords
vectors
improved
polyethyleneglycol
polyethyleneimine
peg
Prior art date
Application number
PH12016502258A
Inventor
Levitzki Alex
Joubran Salim
Shir Alexei
Zigler Maya
Talhami Alaa
Langut Yael
Original Assignee
Alex Levitzki Man And Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alex Levitzki Man And Holdings Ltd filed Critical Alex Levitzki Man And Holdings Ltd
Publication of PH12016502258A1 publication Critical patent/PH12016502258A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Abstract

A polyplex of a double stranded RNA and a polymeric conjugate is provided, wherein the polymeric conjugate consists of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties, each PEG moiety being conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.
PH12016502258A 2014-05-14 2016-11-11 Improved polyethyleneimine polyethyleneglycol vectors PH12016502258A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993110P 2014-05-14 2014-05-14
PCT/IL2015/050514 WO2015173824A1 (en) 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors

Publications (1)

Publication Number Publication Date
PH12016502258A1 true PH12016502258A1 (en) 2017-02-27

Family

ID=54479412

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016502258A PH12016502258A1 (en) 2014-05-14 2016-11-11 Improved polyethyleneimine polyethyleneglycol vectors

Country Status (17)

Country Link
US (4) US10278991B2 (en)
EP (1) EP3142673A4 (en)
JP (3) JP6753843B2 (en)
KR (2) KR102589295B1 (en)
CN (3) CN116966310A (en)
AU (2) AU2015260725B2 (en)
BR (1) BR112016026581A2 (en)
CA (1) CA2949017A1 (en)
IL (2) IL287206B2 (en)
MA (1) MA39970A (en)
MX (2) MX2016014881A (en)
NZ (1) NZ727092A (en)
PH (1) PH12016502258A1 (en)
RU (1) RU2771104C2 (en)
SG (2) SG11201609442YA (en)
WO (1) WO2015173824A1 (en)
ZA (1) ZA201608042B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015260725B2 (en) 2014-05-14 2021-02-25 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
DE112016003047B4 (en) * 2015-11-17 2022-10-27 Highlight Therapeutics, S.L. NEW PHARMACEUTICAL COMPOSITION COMPRISING PARTICLES COMPRISING A COMPLEX OF A DOUBLE STRANDED POLYRIBONUCLEOTIDE AND A POLYALKYLENEIMINE
KR102372857B1 (en) * 2016-03-07 2022-03-11 한미약품 주식회사 Polyethylene glycol derivatives and use thereof
CN109790225B (en) * 2016-09-04 2022-09-09 塔尔格免疫治疗有限公司 Chimeric proteins for targeting dsRNA
EP3448363B1 (en) 2017-05-17 2022-05-11 Highlight Therapeutics, S.L. Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
EP3688008A1 (en) 2017-09-27 2020-08-05 TargImmune Therapeutics AG Castration resistant prostate cancer
JP2021516056A (en) * 2018-03-08 2021-07-01 ターグイミューン セラピューティクス アーゲー Recombinant protein containing double-stranded RNA-binding domain
CN109893657B (en) * 2019-02-28 2022-04-29 中国人民解放军军事科学院军事医学研究院 Gene delivery carrier, drug compound, anti-pulmonary fibrosis drug and application
CA3131535A1 (en) 2019-04-03 2020-10-08 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
WO2020263782A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Methods and compositions for modifying nucleic acids and for killing cells
WO2021001023A1 (en) * 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy
IL301906A (en) 2020-10-08 2023-06-01 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
CA3237153A1 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
US20240091348A1 (en) * 2022-09-20 2024-03-21 Highlight Therapeutics, S.L. Novel compositions based on polyinosinic-polycytidylic acid

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59106279D1 (en) 1990-05-18 1995-09-21 Genentech Inc NEW PROTEIN POLYCATION CONJUGATES.
DE4104186A1 (en) 1991-02-12 1992-08-13 Genentech Inc NEW COMPLEXES INCLUDING ENDOCYTOSIS IN HIGHER EUKARYOTIC CELLS, NUCLEIC ACID
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
DE19726186A1 (en) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Complexes for the transport of nucleic acid into higher eukaryotic cells
WO1999061032A1 (en) 1998-05-25 1999-12-02 Nippon Shinyaku Co., Ltd. Process for producing composite preparation containing nucleic acid
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20040043030A1 (en) 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
GB0119346D0 (en) 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
US20040105839A1 (en) 2001-11-28 2004-06-03 Myung-Ok Park Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
WO2003072636A1 (en) 2002-02-28 2003-09-04 Jong Sang Park Cationic highly branched polyaminoester
SG166672A1 (en) 2002-08-06 2010-12-29 Intradigm Corp Methods of down regulating target gene expression in vivo by introduction of interfering rna
WO2004045491A2 (en) * 2002-11-18 2004-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted double stranded rna mediated cell killing
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US8324365B2 (en) 2003-04-03 2012-12-04 Korea Advanced Institute Of Science And Technology Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050118718A1 (en) 2003-09-22 2005-06-02 University Of Utah Research Foundation Stabilization and controlled delivery of ionic biopharmaceuticals
WO2005090570A1 (en) 2004-03-24 2005-09-29 Supratek Pharma Inc. Therapeutic compositions and methods for treating diseases that involve angiogenesis
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CN101287500A (en) * 2005-08-19 2008-10-15 恩多塞特公司 Multi-drug ligand conjugates
WO2007133812A2 (en) 2005-12-30 2007-11-22 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
WO2007084797A1 (en) 2006-01-23 2007-07-26 Abbott Laboratories Chemically modified polycation polymer for sirna delivery
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
EP2007435B1 (en) 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
PT2644594T (en) 2007-09-28 2017-11-20 Pfizer Cancer cell targeting using nanoparticles
JP2011500569A (en) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー Vaccine nanotechnology
US20110027172A1 (en) 2007-12-10 2011-02-03 Zhuang Wang Drug delivery system for pharmaceuticals and radiation
WO2009086640A1 (en) 2008-01-10 2009-07-16 Nventa Biopharmaceuticals Corporation Adjuvant compositions comprising poly-ic and a cationic polymer
WO2009131435A1 (en) 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
EP2113257A1 (en) 2008-04-30 2009-11-04 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer
EP2123304A1 (en) 2008-05-23 2009-11-25 Freie Universität Berlin Compounds suited as nanocarriers for active agents and their use
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2010005740A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
CA2748125A1 (en) * 2008-12-22 2010-07-01 Alexander Levitzki Egfr-homing double-stranded rna vector for systemic cancer treatment
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
US20100266642A1 (en) 2009-02-20 2010-10-21 Bind Biosciences, Inc. Modified cells for targeted cell trafficking and uses thereof
WO2010114169A1 (en) 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US8287910B2 (en) 2009-04-30 2012-10-16 Intezyne Technologies, Inc. Polymeric micelles for polynucleotide encapsulation
ES2368963B1 (en) 2009-07-04 2012-10-10 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii PROCEDURE FOR IDENTIFICATION OF THERAPEUTIC AGENTS AGAINST MELANOMA AND USE OF IDENTIFIED AGENT.
CN101638484A (en) * 2009-08-24 2010-02-03 中国科学院长春应用化学研究所 Polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine copolymer, preparation method thereof and application thereof
EP2509629A4 (en) 2009-12-09 2013-06-26 Ibc Pharmaceuticals Inc Dock-and-lock (dnl) complexes for delivery of interference rna
EA201290498A1 (en) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. THERAPEUTIC POLYMER NANOPARTICLES, INCLUDING EPOTILON, AND METHODS FOR THEIR PREPARATION AND APPLICATION
WO2011084518A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
JP5965844B2 (en) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド Therapeutic polymer nanoparticle compositions having high glass transition temperature or high molecular weight copolymers
MX2012009178A (en) 2010-02-24 2012-11-30 Arrowhead Res Corp Compositions for targeted delivery of sirna.
ES2631458T3 (en) 2010-03-04 2017-08-31 Interna Technologies B.V. MRNA molecule defined by its source and its therapeutic uses in cancer associated with EMT
US20110256227A1 (en) 2010-04-14 2011-10-20 Intezyne Technologies, Inc. Controlled polyplex assembly
EP2395041A1 (en) 2010-06-10 2011-12-14 F. Hoffmann-La Roche AG Polymers for delivery of nucleic acids
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
CA2804599C (en) 2010-07-06 2023-01-31 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US20120207795A1 (en) 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
FR2963350B1 (en) 2010-07-30 2013-11-01 Univ D Evry Val D Essonne NOVEL BLOCK COPOLYMERS AND THEIR USES FOR DELIVERING AN ACTIVE SUBSTANCE INTO A CELL.
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8461224B2 (en) 2011-03-04 2013-06-11 National Health Research Institutes Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery
EP2691120A4 (en) 2011-03-31 2014-09-24 Univ Johns Hopkins Theranostic imaging agents and methods of use
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
AU2013256471A1 (en) 2012-05-02 2014-11-13 Arrowhead Research Corporation Organic compositions to treat KRAS-related diseases
HUE029977T2 (en) 2012-07-12 2017-04-28 Proqr Therapeutics Ii Bv Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
CA2912975A1 (en) 2012-10-16 2014-04-24 William Marsh Rice University An improved nanovector based drug delivery system for overcoming drug resistance
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
WO2014078484A1 (en) 2012-11-15 2014-05-22 Endocyte, Inc. Conjugates for treating diseases caused by psma expressing cells
WO2014088087A1 (en) 2012-12-06 2014-06-12 協和発酵バイオ株式会社 Double-stranded ribonucleic acid for adjuvants
US20170021036A1 (en) 2013-06-22 2017-01-26 Ethris Gmbh Compositions for introducing rna into cells
CN104341488A (en) 2013-08-02 2015-02-11 复旦大学 c(LyP-1) polypeptide and nano-delivery system constructed thereby and application of nano-delivery system
US20160312218A1 (en) 2013-11-04 2016-10-27 Northeastern University System for co-delivery of polynucleotides and drugs into protease-expressing cells
US20160271268A1 (en) 2013-11-08 2016-09-22 Dana-Farber Cancer Institute, Inc. Nucleic acid nanostructures for in vivo agent delivery
BR112016021130A2 (en) 2014-03-14 2017-08-15 Pfizer THERAPEUTIC NANOPARTICLES, PHARMACEUTICAL COMPOSITION INCLUDING THE SAID NANOPARTICLES, PROCESS FOR THE PREPARATION AND USE THEREOF
EP3126501A1 (en) 2014-03-24 2017-02-08 RiboxX GmbH Double-stranded rna conjugates and their use
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
AU2015260725B2 (en) * 2014-05-14 2021-02-25 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
EP3253414A4 (en) 2015-02-05 2018-07-11 The University Of Queensland Targeting constructs for delivery of payloads
US20160331845A1 (en) 2015-05-14 2016-11-17 The Johns Hopkins University Compositions of nucleic acid-containing nanoparticles for in vivo delivery
DE112016003047B4 (en) 2015-11-17 2022-10-27 Highlight Therapeutics, S.L. NEW PHARMACEUTICAL COMPOSITION COMPRISING PARTICLES COMPRISING A COMPLEX OF A DOUBLE STRANDED POLYRIBONUCLEOTIDE AND A POLYALKYLENEIMINE

Also Published As

Publication number Publication date
IL248890A0 (en) 2017-01-31
NZ764423A (en) 2021-08-27
US10543232B2 (en) 2020-01-28
MX2020012698A (en) 2021-02-15
MX2016014881A (en) 2017-05-01
KR102472590B1 (en) 2022-11-30
JP6753843B2 (en) 2020-09-16
JP2020196739A (en) 2020-12-10
US20190192563A1 (en) 2019-06-27
AU2015260725B2 (en) 2021-02-25
SG10201911695SA (en) 2020-01-30
KR102589295B1 (en) 2023-10-13
RU2771104C2 (en) 2022-04-26
CN116966310A (en) 2023-10-31
CN116966311A (en) 2023-10-31
JP2017521090A (en) 2017-08-03
CN106687121A (en) 2017-05-17
IL287206B1 (en) 2023-10-01
US10278991B2 (en) 2019-05-07
IL248890B (en) 2021-10-31
AU2015260725A1 (en) 2016-12-22
NZ727092A (en) 2021-07-30
US20170072063A1 (en) 2017-03-16
US11298376B2 (en) 2022-04-12
JP7406475B2 (en) 2023-12-27
KR20170005052A (en) 2017-01-11
WO2015173824A1 (en) 2015-11-19
CA2949017A1 (en) 2015-11-19
IL287206A (en) 2021-12-01
BR112016026581A2 (en) 2017-10-31
US20220339189A1 (en) 2022-10-27
MA39970A (en) 2015-11-19
JP2024028995A (en) 2024-03-05
EP3142673A4 (en) 2018-01-03
AU2021203336A1 (en) 2021-06-24
RU2016146389A (en) 2018-06-15
EP3142673A1 (en) 2017-03-22
SG11201609442YA (en) 2016-12-29
RU2016146389A3 (en) 2018-12-26
KR20220163536A (en) 2022-12-09
US20190262395A1 (en) 2019-08-29
IL287206B2 (en) 2024-02-01
ZA201608042B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
MX2020012698A (en) Improved polyethyleneimine polyethyleneglycol vectors.
HK1259487A1 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
WO2015151080A3 (en) Specific conjugation of cell-binding molecules
ZA201805336B (en) Amanitin conjugates
IL268888A (en) Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, cea, or claudin-18.2
PH12019501056A1 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2015151078A3 (en) Hydrophilic linkers for conjugation
ZA201706745B (en) Site-specific antibody-drug conjugates
IL279133A (en) Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
MX2013003452A (en) Amatoxin-conjugates with improved linkers.
MX2013010286A (en) Amatoxin-conjugates with improved linkages.
MX2015005794A (en) Oligonucleotide conjugates.
EA201992456A2 (en) SELF-STABILIZING LINKER CONJUGATES
MX2016009862A (en) Hydrophilic antibody-drug conjugates.
EA201401254A1 (en) САМОСТАБИЛИЗИРУСЩИЕСЯ ЛИНКЕРНЫЕ КОНЪЮГАТЫ
MX2017002333A (en) Novel glycan conjugates and use thereof.
MX2020001138A (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof.
MX2018001511A (en) Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same.
IL264845B1 (en) Malignant tumor targeting peptides, conjugates and compositions comprising same and uses thereof
WO2016147031A3 (en) Novel hydrophilic linkers and ligand-drug conjugates thereof
ZA202001747B (en) Psma-targeting amanitin conjugates
TN2016000445A1 (en) Igf-1r antibody and its use as addressing vehicle for the treatment of cancer.
SG11202001602QA (en) Peptide conjugates, conjugation process, and uses thereof
SG10202105348WA (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
AR110347A1 (en) ANTI-KREMEN2 ANTIBODIES AND METHODS FOR USE